Evaluation of the Frequency of Occurrence of Joint Pain With Bevacizumab in Patients With Ovarian, Colorectal or Bronchopulmonary Cancer

University Hospital, Lille71 enrolled

Overview

Self-administered questionnaire survey to determine the presence or absence of joint pain during bevacizumab treatment for lung, ovarian, colorectal cancers. The principal end-point is the frequency of arthralgia after 6 months of treatment with Bevacizumab.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Arthralgia

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with ovarian, colorectal or lung cancer receiving bevacizumab therapy * Male or female (aged ≥18 years old) * Performance Status (PS) between 0 and 2 * Expected life\> 3 months * Ability to answer a self-questionnaire * Obtaining the non-opposition of patient participation Exclusion Criteria: * Pregnant or lactating woman * Rapid evolution of neoplastic pathology * Major cognitive disorders that do not allow filling of the self-questionnaire * Impossibility to submit to medical monitoring for social, psychological or geographical reasons * Patients under guardianship or curatorship

Locations (2)

Centre Oscar Lambret

Lille, France

Hôpital Huriez. CHRU

Lille, France

Outcomes

Primary Outcomes

Frequency of arthralgia

Frequency of joint manifestations of any grade according to the CTCAE (Common Terminology Criteria for Adverse Events) scale version 4.0 observed between the start of bevacizumab treatment and 6 months of treatment.

Time frame: At 6 months

Secondary Outcomes

correlation between global cancer response and occurrence of arthralgia

Time frame: baseline, at 3 months, at 6 months

auto questionnaire specific to the study

16 questions concerning the location, intensity, management of joint pain

Time frame: Baseline at 3 months, at 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.